Real-time
Euronext Paris
02:02:45 17/07/2024 pm IST
5-day change
1st Jan Change
2.29
EUR
-4.58%
-23.67%
+59.03%
Nfl Biosciences: Half-Year Review of the Liquidity Agreement for h2 2021
January 12, 2022 at 10:16 pm IST
NFL BIOSCIENCES HALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H2 2021
Under the liquidity agreement concerning NFL Biosciences SA shares (FR0014003XT0 - ALNFL), entrusted to Invest Securities , the following resources were recorded in the liquidity account at December 31, 2021 :
48,465 NFL BIOSCIENCES securities €48,970 of cash During the second half of 2021, the following trades were recorded:
PURCHASES 79,349 securities €264,254.05 590 transactions SALES 29,884 securities €109,132.02 347 transactions
For reference, the following resources were recorded in the liquidity account at July 7, 2021 :
0 securities €200,000 of cash For reference, when the new liquidity agreement was set up, the following resources were made available:
0 securities €200,000 of cash N.B. On July 16, 2021 , compensation for buyback of 1,000 securities: €4,092
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based nearby Montpellier, France , whose most advanced botanical drug candidate is an aid to stop smoking. Known as NFL-101, this natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. NFL Biosciences aims to offer smokers who would like to stop smoking a safe, natural solution that is effective over the long-term, with short-term personalized administration.
Alongside NFL-101, NFL Biosciences has various development projects focused on botanical drugs for the treatment of cannabis use disorder and alcoholism.
The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com
Contact
NFL Biosciences : Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67
PR Agency : Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 68
Appendix:
Volume of purchases and sales in terms of the number of securities and the amount of capital on an aggregate basis per trading day during the second half of 2021
Purchases Sales Date Number of securities Capital (EUR) Number of securities Capital (EUR) 07/07/21 2,106 7,284.65 0.00 08/07/21 13,000 41,145.00 0.00 09/07/21 4,026 12,665.39 0.00 12/07/21 2,282 7,441.60 0.00 13/07/21 3,514 11,905.43 0.00 14/07/21 5,070 16,356.33 0.00 15/07/21 995 3,200.92 0.00 16/07/21 0.00 0.00 16/07/21 0.00 0.00 19/07/21 0.00 0.00 19/07/21 0.00 0.00 20/07/21 912 2,991.36 0.00 20/07/21 0.00 251 832.32 21/07/21 2,636 8,661.90 0.00 21/07/21 0.00 1 3.38 22/07/21 2,095 7,428.87 0.00 22/07/21 0.00 3,021 10,733.61 23/07/21 2,790 9,812.43 0.00 23/07/21 0.00 1 3.65 26/07/21 1,612 5,472.74 0.00 26/07/21 0.00 381 1,322.45 27/07/21 357 1,209.16 0.00 27/07/21 0.00 1 3.43 28/07/21 461 1,581.23 0.00 28/07/21 0.00 190 683.81 29/07/21 204 682.38 0.00 29/07/21 0.00 126 438.48 30/07/21 115 390.66 0.00 30/07/21 0.00 109 385.64 02/08/21 126 441.00 0.00 03/08/21 251 865.95 0.00 03/08/21 0.00 1 3.50 04/08/21 887 3,176.35 0.00 04/08/21 0.00 2,446 9,150.49 05/08/21 191 702.69 0.00 05/08/21 0.00 1 3.70 06/08/21 41 147.64 0.00 06/08/21 0.00 301 1,113.70 09/08/21 301 1,128.75 0.00 09/08/21 0.00 1,951 7,671.33 10/08/21 1,651 6,379.46 0.00 10/08/21 0.00 1,651 6,582.54 11/08/21 396 1,427.18 0.00 11/08/21 0.00 151 573.65 12/08/21 301 1,038.45 0.00 12/08/21 0.00 1 3.60 13/08/21 1 3.50 0.00 13/08/21 0.00 151 528.50 16/08/21 240 831.12 0.00 16/08/21 0.00 1 3.59 17/08/21 62 210.92 0.00 17/08/21 0.00 21 73.50 18/08/21 151 513.40 0.00 18/08/21 0.00 1 3.42 19/08/21 151 513.40 0.00 19/08/21 0.00 1 3.40 20/08/21 1 3.50 0.00 20/08/21 0.00 21 73.50 23/08/21 151 513.40 0.00 23/08/21 0.00 1 3.42 24/08/21 151 513.40 0.00 24/08/21 0.00 1 3.44 25/08/21 1 3.50 0.00 25/08/21 0.00 2 7.00 26/08/21 149 506.75 0.00 26/08/21 0.00 8 28.00 27/08/21 3 9.99 0.00 27/08/21 0.00 253 870.32 30/08/21 1 3.57 0.00 30/08/21 0.00 1 3.57 31/08/21 1 3.37 0.00 31/08/21 0.00 151 528.35 01/09/21 1 3.41 0.00 01/09/21 0.00 151 528.35 02/09/21 1 3.50 0.00 02/09/21 0.00 1 3.50 03/09/21 151 513.55 0.00 03/09/21 0.00 151 543.45 06/09/21 151 528.65 0.00 06/09/21 0.00 151 548.13 07/09/21 151 528.50 0.00 07/09/21 0.00 1 3.51 08/09/21 301 1,038.45 0.00 08/09/21 0.00 1 3.53 09/09/21 151 513.40 0.00 09/09/21 0.00 1 3.46 10/09/21 1 3.34 0.00 10/09/21 0.00 1 3.34 13/09/21 151 513.40 0.00 13/09/21 0.00 1 3.40 14/09/21 1 3.35 0.00 14/09/21 0.00 1 3.35 15/09/21 1 3.34 0.00 15/09/21 0.00 1 3.34 16/09/21 1 3.35 0.00 16/09/21 0.00 452 1,582.00 17/09/21 301 1,068.55 0.00 17/09/21 0.00 1 3.60 20/09/21 171 583.45 0.00 20/09/21 0.00 1 3.50 21/09/21 151 513.40 0.00 21/09/21 0.00 1 3.45 22/09/21 251 826.29 0.00 22/09/21 0.00 301 1,068.25 23/09/21 1 3.58 0.00 23/09/21 0.00 300 1,095.00 24/09/21 1 3.71 0.00 24/09/21 0.00 1 3.71 27/09/21 1 3.70 0.00 27/09/21 0.00 1 3.70 28/09/21 1 3.65 0.00 28/09/21 0.00 1 3.65 29/09/21 1 3.62 0.00 29/09/21 0.00 440 1,707.64 30/09/21 485 1,887.62 0.00 30/09/21 0.00 243 966.65 01/10/21 1 3.95 0.00 01/10/21 0.00 98 387.10 04/10/21 151 583.01 0.00 04/10/21 0.00 1 3.94 05/10/21 210 802.41 0.00 05/10/21 0.00 2,943 11,727.86 06/10/21 151 588.90 0.00 06/10/21 0.00 1 3.95 07/10/21 1 3.90 0.00 07/10/21 0.00 1 3.90 08/10/21 751 3,318.67 0.00 08/10/21 0.00 3,001 13,411.47 11/10/21 901 3,724.73 0.00 11/10/21 0.00 151 604.30 12/10/21 1 3.99 0.00 12/10/21 0.00 451 1,849.10 13/10/21 1 4.01 0.00 13/10/21 0.00 1 4.01 14/10/21 151 619.10 0.00 14/10/21 0.00 151 634.20 15/10/21 301 1,219.05 0.00 15/10/21 0.00 1 4.17 18/10/21 1 3.99 0.00 18/10/21 0.00 23 94.19 19/10/21 1 4.10 0.00 19/10/21 0.00 122 500.20 20/10/21 1 4.04 0.00 20/10/21 0.00 158 647.80 21/10/21 3,818 14,756.57 0.00 21/10/21 0.00 1 4.10 22/10/21 1 3.84 0.00 22/10/21 0.00 151 588.90 25/10/21 151 585.88 0.00 25/10/21 0.00 1 3.88 26/10/21 1 3.90 0.00 26/10/21 0.00 1 3.90 27/10/21 151 588.90 0.00 27/10/21 0.00 1 3.95 28/10/21 151 588.90 0.00 28/10/21 0.00 1 3.90 29/10/21 151 588.90 0.00 29/10/21 0.00 1 3.90 01/11/21 151 573.80 0.00 01/11/21 0.00 151 588.90 02/11/21 151 573.80 0.00 02/11/21 0.00 1 3.87 03/11/21 1 3.73 0.00 03/11/21 0.00 1 3.73 04/11/21 501 1,870.73 0.00 04/11/21 0.00 373 1,446.87 05/11/21 301 1,128.75 0.00 05/11/21 0.00 1 3.90 08/11/21 151 573.80 0.00 08/11/21 0.00 1 3.80 09/11/21 151 573.65 0.00 09/11/21 0.00 1 3.72 10/11/21 1 3.78 0.00 10/11/21 0.00 1 3.78 11/11/21 1 3.73 0.00 11/11/21 0.00 32 121.54 12/11/21 151 558.85 0.00 12/11/21 0.00 120 456.00 15/11/21 204 769.90 0.00 15/11/21 0.00 1 3.84 16/11/21 1 3.71 0.00 16/11/21 0.00 301 1,158.85 17/11/21 548 2,079.11 0.00 17/11/21 0.00 3 11.94 18/11/21 1 3.70 0.00 18/11/21 0.00 1 3.70 19/11/21 151 543.60 0.00 19/11/21 0.00 153 566.10 22/11/21 1 3.64 0.00 22/11/21 0.00 301 1,106.18 23/11/21 151 558.70 0.00 23/11/21 0.00 299 1,128.73 24/11/21 1 3.64 0.00 24/11/21 0.00 152 577.45 25/11/21 67 247.83 0.00 25/11/21 0.00 151 573.65 26/11/21 6,805 23,769.87 0.00 26/11/21 0.00 151 513.70 29/11/21 5,129 15,797.32 0.00 29/11/21 0.00 651 2,235.53 30/11/21 151 440.92 0.00 30/11/21 0.00 751 2,334.11 01/12/21 441 1,392.24 0.00 01/12/21 0.00 151 490.75 02/12/21 256 783.87 0.00 02/12/21 0.00 1 3.19 03/12/21 1 2.99 0.00 03/12/21 0.00 304 950.00 06/12/21 121 377.64 0.00 06/12/21 0.00 3 9.60 07/12/21 831 2,370.84 0.00 07/12/21 0.00 446 1,449.50 08/12/21 126 350.28 0.00 08/12/21 0.00 1 2.80 09/12/21 376 1,067.84 0.00 09/12/21 0.00 751 2,177.90 10/12/21 501 1,350.20 0.00 10/12/21 0.00 301 803.67 13/12/21 126 330.25 0.00 13/12/21 0.00 151 401.66 14/12/21 1 2.65 0.00 14/12/21 0.00 912 2,576.40 15/12/21 4,231 10,729.82 0.00 15/12/21 0.00 1,844 5,336.54 16/12/21 201 472.35 0.00 16/12/21 0.00 1 2.38 17/12/21 1 2.35 0.00 17/12/21 0.00 151 354.85 20/12/21 101 240.38 0.00 20/12/21 0.00 151 362.40 21/12/21 1 2.40 0.00 21/12/21 0.00 1 2.40 22/12/21 1 2.42 0.00 22/12/21 0.00 1 2.42 23/12/21 1 2.50 0.00 23/12/21 0.00 301 758.52 24/12/21 1 2.45 0.00 24/12/21 0.00 1 2.45 27/12/21 101 242.40 0.00 27/12/21 0.00 1 2.43 28/12/21 1 2.40 0.00 28/12/21 0.00 151 368.44 29/12/21 1 2.49 0.00 29/12/21 0.00 1 2.49 30/12/21 102 246.84 0.00 30/12/21 0.00 1 2.47 31/12/21 200 468.00 0.00 31/12/21 0.00 1 2.38 Total 79,349 264,254.05 29,884 109,132.02
NFLBiosciences_bilan_CL_S2_2021_EN
© OMX, source GlobeNewswire - EU Press Releases
NFL Biosciences: potential in smoking cessation confirmed
15/07
CF
NFL BIOSCIENCES : Invest Securities raises its target
15/07
CF
NFL Biosciences: study with CEA presented at congress
29/05
CF
NFL Biosciences receives positive feedback from the FDA
21/05
CF
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...
12/04
NFL Biosciences: successful capital increase
12/04
CF
NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships
12/04
MT
NFL Biosciences: success of smoking cessation study
30/01
CF
NFL Biosciences Announces Patent Application Filed in the United States for Reducing Alcohol Consumption with NFL-301 & Preparation of a Pre-Ind Application Submission with the FDA
18/23/18
CI
NFL Biosciences: GB Holding raises its stake
30/23/30
CF
Global markets live: ABB, Bayer, UBS, Apple, Microsoft...
25/23/25
NFL Biosciences SA Announces Management Changes
27/23/27
CI
NFL BIOSCIENCES Announces Inclusion of the First Volunteer in the PRECESTO Study
22/23/22
CI
Global markets live: Airbus, Walmart, Meta, Home Depot...
21/23/21
NFL Biosciences SA announced that it has received 1.7 million in funding from Bpifrance Investissement SAS
20/23/20
CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing...
31/23/31
NFL Biosciences Raises EUR3 Million In Latest Funding Round
31/23/31
MT
NFL Biosciences Kicks Off Nearly EUR3 Million Fundraising
31/23/31
MT
NFL Biosciences On Track to Complete Trial on Smoking Cessation Treatment by Year-end
20/23/20
MT
NFL Biosciences Announces CESTO II Trial Progressing on Schedule
20/23/20
CI
NFL Biosciences SA Announces Clinical Trial Approved to Demonstrate the Complementarity of NFL-101 with Other Smoking Cessation Treatments
08/22/08
CI
Themis Medicare Partners with NFL Biosciences to Develop Anti-Smoking Drug in India
07/22/07
MT
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India
05/22/05
CI
1,959,385 Ordinary Shares of Nfl Biosciences are subject to a Lock-Up Agreement Ending on 5-JUL-2022.
05/22/05
CI
NFL Biosciences Wins Nod To Issue Patent For Smoking Addiction Treatment Candidate In South Korea
12/22/12
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.
At the end of 2023, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
More about the company
Average target price
4.2
EUR
Spread / Average Target
+75.00%
Consensus
1st Jan change
Capi.
+59.03% 25.35M +20.17% 126B +24.67% 118B +24.05% 27.87B -17.74% 20.95B -15.15% 16.92B -15.21% 16.18B +11.91% 14.84B -47.10% 14.79B +54.50% 14.08B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1